Clinical trialNCT00657501CompletedPhase 3Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

SponsorBioSante PharmaceuticalsEnrollment575Hypoactive Sexual Desire Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel 300mcg in the treatment of HSDD in surgically menopausal women.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Michael C Snabes, MD, PhD
BioSante Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

69 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Biosante Site #175
Vancouver, British Columbia, Canada
Biosante Site #123
Ottawa, Ontario, Canada
Biosante Site #109
Québec, Quebec, Canada

United States

Biosante Site #146
Mobile, Alabama, United States
Biosante Site #171
Chandler, Arizona, United States
Biosante Site #145
Glendale, Arizona, United States
Biosante Site #121
Phoenix, Arizona, United States
Biosante Site #137
Tucson, Arizona, United States
Biosante Site #100
Jonesboro, Arkansas, United States
Biosante Site #155
Little Rock, Arkansas, United States
Biosante Site #221
Berkely, California, United States
Biosante Site #162
Sacramento, California, United States
Biosante Site #112
San Diego, California, United States
Biosante Site #159
Walnut Creek, California, United States
Biosante Site #026
Lakewood, Colorado, United States
Biosante Site #166
Farmington, Connecticut, United States
Biosante Site #132
New Britain, Connecticut, United States
Biosante Site #151
New London, Connecticut, United States
Biosante Site #143
Jacksonville, Florida, United States
Biosante Site #111
Orlando, Florida, United States
Biosante Site #152
Tampa, Florida, United States
Biosante Site #115
Atlanta, Georgia, United States
Biosante Site #141
Roswell, Georgia, United States
Biosante Site #202
Idaho Falls, Idaho, United States
Biosante Site #017
Meridian, Idaho, United States
Biosante Site #156
Champaign, Illinois, United States
Biosante Site #045
Chicago, Illinois, United States
Biosante Site #133
Chicago, Illinois, United States
Biosante Site #149
Chicago, Illinois, United States
Biosante Site #167
Newburgh, Indiana, United States
Biosante Site #163
Overland Park, Kansas, United States
Biosante Site #136
Lexington, Kentucky, United States
Biosante Site #214
Lexington, Kentucky, United States
Biosante Site #157
Mandeville, Louisiana, United States
Biosante Site #110
Metarie, Louisiana, United States
Biosante Site #035
Ann Arbor, Michigan, United States
Biosante Site #124
Bingham Farms, Michigan, United States
Biosante Site #105
Kalamazoo, Michigan, United States
Biosante Site #104
St Louis, Missouri, United States
Biosante Site #127
Billings, Montana, United States

29 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Placebo gelTestosterone gel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2008
Primary completion: 30 Sept 2011
Completion: 30 Sept 2011
Last update posted: 10 Jan 2013
Registered enrollment: 575
Registry id: NCT00657501

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.